ID 630 -
Kwas dokozaheksaenowy
PL: Kwas dokozaheksaenowy
EN: Docosahexaenoic acid (DHA)
Pdf: docosahexaenoic acid
Oświadczenie (2)
- wspierających środków w celu obniżenia poziomu cholesterolu utlenionej
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is docosahexaenoic acid (DHA), which is a well characterised n-3 long-chain fatty acid that can be quantified in foods by established methods. The absorption of DHA is well documented. This evaluation applies to all sources of DHA in the specified amounts.
The Panel considers that the food constituent, DHA, which is the subject of the health claims is sufficiently characterised.
2.2. Ochrona lipidów we krwi przed uszkodzeniem oksydacyjnym (ID 630)
The claimed effect is “supportive measure to reduce the level of oxidised cholesterol”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the protection of blood lipids (LDL-cholesterol particles) from oxidative damage.
Reactive oxygen species (ROS) including several kinds of radicals are generated in biochemical processes (e.g. respiratory chain) and as a consequence of exposure to exogenous noxes (e.g. radiation, pollutants). These reactive intermediates damage biologically relevant molecules such as DNA, proteins and lipids if they are not intercepted by the antioxidant network, which includes free radical scavengers such as antioxidant nutrients.
The Panel considers that protection of blood lipids from oxidative damage may be a beneficial physiological effect.
3.2. Ochrona lipidów we krwi przed uszkodzeniem oksydacyjnym (ID 630)
The references provided for the substantiation of the claimed effect included animal and intervention studies on the combined effects of EPA plus DHA on different outcomes, including LDL oxidation. The Panel considers that no scientific conclusions can be drawn from these references in relation to the role of DHA alone in protecting blood lipids from oxidative damage.
Three of the references presented reported on RCTs (Mori et al., 2000; Woodman et al., 2003; Kelley et al., 2007) which investigated the effects of DHA supplementation on LDL particle size and/or the serum concentrations of small and dense LDL particles in humans. None of the studies directly addressed the effects of DHA supplementation on LDL oxidation.
The Panel concludes that a cause and effect relationship has not been established between the consumption of DHA and the protection of blood lipids from oxidative damage.
Warunki i możliwe ograniczenia stosowania oświadczenia
At least 220 mg DHA/day, based on a 2000 kcal diet.